AI주식인사이트AI Stock Insight
C

CMG제약

058820KOSDAQ의약품 제조업

45.0 / 100

Reference Date: 2026-04-13

Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 3.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CMG Pharmaceutical is a core subsidiary of Chabiotech Group, specializing in the R&D, production, and sales of pharmaceuticals and health functional foods. The company focuses on developing improved new drugs using its proprietary STARFILM Technology, which enables unique taste and stability in oral disintegrating films (ODF). It is expanding into high-growth sectors such as oncology, anti-aging, ophthalmology, and maternal and baby care, while also operating an animal pharmaceutical business through its subsidiaries to enhance shareholder value.

Number of Employees

206people

Average Salary

62.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 14.804.0Point
PBR
1.30Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE
-5.15Industry Average 4.420.0Point

Well below industry avg

Debt Ratio
0.37Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲5.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼264.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -0.1% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 1,773Won52-week high 2,97552-week low 1,675
1-month return4.0Point

1m +3.62% (slight rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral정기주주총회결과2026-03-27
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
  • Neutral감사보고서제출2026-03-19
  • Neutral사업보고서 (2025.12)2026-03-19